Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.82 USD
+0.53 (0.60%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $88.74 -0.08 (-0.09%) 4:46 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.82 USD
+0.53 (0.60%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $88.74 -0.08 (-0.09%) 4:46 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion
by Zacks Equity Research
Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $75.65, marking a +0.81% move from the previous day.
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
Gilead (GILD) to Launch Generics for Leading HCV Treatments
by Zacks Equity Research
Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
CHMP Reconfirms Negative Opinion for Sarepta's Exondys
by Zacks Equity Research
The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Rubius (RUBY) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
by Zacks Equity Research
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Ultragenyx's Shares Surge More Than 80% in the Year So Far
by Zacks Equity Research
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $73.88, marking a +0.31% move from the previous day.
Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success
by Zacks Equity Research
Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.
Viking Therapeutics Liver Candidate Passes Test, Shares Soar
by Zacks Equity Research
Viking Therapeutics (VKTX) pipeline candidate, VK2809, achieves statistically significant reduction in liver fat content and bad cholesterol levels in a phase II study, evaluated for NAFLD.
Dr. Reddy's (RDY) Presence in Generics Market Remains Strong
by Zacks Equity Research
Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.
Is Gilead (GILD) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Gilead Sciences, Inc. (GILD) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Theravance, Mylan Report Positive Data on COPD Drug Yupelri
by Zacks Equity Research
Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.
Agenus Receives Milestone Payment of $5 Million from Incyte
by Zacks Equity Research
Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.
Should Value Investors Pick Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.
Unity (UBX) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Company News For Sep 13, 2018
by Zacks Equity Research
Companies in the news are: GILD, VZ, BHC and WBC